Sabrina Martyr

3.6k total citations · 1 hit paper
18 papers, 2.5k citations indexed

About

Sabrina Martyr is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Sabrina Martyr has authored 18 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 8 papers in Hematology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Sabrina Martyr's work include Chronic Lymphocytic Leukemia Research (7 papers), Hemoglobinopathies and Related Disorders (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Sabrina Martyr is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Hemoglobinopathies and Related Disorders (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Sabrina Martyr collaborates with scholars based in United States, Malaysia and Denmark. Sabrina Martyr's co-authors include Mark T. Gladwin, Gloria Zalos, Myron A. Waclawiw, Jack H. Crawford, Howard Shields, Christopher D. Reiter, Alan N. Schechter, Benjamin Yang, Rakesh P. Patel and Xiuli Xu and has published in prestigious journals such as Nature Medicine, Blood and Clinical Cancer Research.

In The Last Decade

Sabrina Martyr

17 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation

2003 1.4k citations Jack H. Crawford, Rakesh P. Patel et al. Nature Medicine profile →

Peers

Countries citing papers authored by Sabrina Martyr

Since Specialization

Citations

This map shows the geographic impact of Sabrina Martyr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabrina Martyr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabrina Martyr more than expected).

Fields of papers citing papers by Sabrina Martyr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sabrina Martyr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabrina Martyr. The network helps show where Sabrina Martyr may publish in the future.

Co-authorship network of co-authors of Sabrina Martyr

This figure shows the co-authorship network connecting the top 25 collaborators of Sabrina Martyr. A scholar is included among the top collaborators of Sabrina Martyr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sabrina Martyr. Sabrina Martyr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Diagnosis and management of ovarian vein thrombosis in a healthy individual: a case report and a literature review 2016 ·Journal of Thrombosis and Haemostasis ·(unknown), (unknown), Sabrina Martyr, Ke Lü	28
2	Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study 2015 ·Clinical Cancer Research ·Carsten Utoft Niemann, Sarah E. M. Herman, Irina Marić, Julio Gómez‐Rodríguez, Angélique Biancotto, Betty Chang, Sabrina Martyr, Maryalice Stetler‐Stevenson, Constance M. Yuan, Katherine R. Calvo, Raul C. Braylan, Janet Valdez, Yuh Shan Lee, Deanna H. Wong, Jade Jones, Clare Sun, Gerald E. Marti, Mohammed Farooqui, Adrian Wiestner	160
3	Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy 2015 ·Clinical Cancer Research ·Martin Skarzynski, Carsten Utoft Niemann, Yuh Shan Lee, Sabrina Martyr, Irina Marić, Dalia Salem, Maryalice Stetler‐Stevenson, Gerald E. Marti, Katherine R. Calvo, Constance M. Yuan, Janet Valdez, Susan Soto, Mohammed Farooqui, Sarah E. M. Herman, Adrian Wiestner	62
4	Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib 2015 ·Haematologica ·Andrew Lipsky, Mohammed Z.H. Farooqui, Xin Tian, Sabrina Martyr, Ann Cullinane, Khanh Nghiem, Clare Sun, Janet Valdez, Carsten Utoft Niemann, Sarah E.M. Herman, Nakhle S. Saba, S. Soto, Gerald E. Marti, Gülbû Uzel, Steven M. Holland, Jay N. Lozier, Adrian Wiestner	131
5	Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study 2014 ·Leukemia ·Sarah E. M. Herman, Carsten Utoft Niemann, Mahfooz Farooqui, Jeffrey A. Jones, Rashida Z. Mustafa, Andrew Lipsky, Nakhle S. Saba, Sabrina Martyr, S. Soto, Joseph M. Valdez, (unknown), I. Maric, Katherine R. Calvo, Lone Bredo Pedersen, Geisler Ch, Danping Liu, Gerald E. Marti, Georg Aue, Adrian Wiestner	131
6	Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p 2013 ·Blood ·Mohammed Farooqui, Georg Aue, Janet Valdez, Sabrina Martyr, Jade Jones, Susan Soto, Maryalice Stetler‐Stevenson, Constance M. Yuan, Diane C. Arthur, Francine Thomas, Xin Tian, Delong Liu, Irina Marić, Adrian Wiestner	15
7	Effective Inhibition Of Tumor Microenvironment Interactions In CLL Patients Treated With The BTK Inhibitor Ibrutinib Results In Sustained Inhibition Of Tumor Proliferation and Survival Pathways 2013 ·Blood ·Sarah E. M. Herman, Rashida Z. Mustafa, Sabrina Martyr, (unknown), Janet Valdez, Susan Soto, Mohammed Farooqui, Adrian Wiestner	0
8	A Pilot Study Of Rituximab In Patients With Moderate Aplastic Anemia, Diamond-Blackfan Anemia and Pure Red Cell Aplasia 2013 ·Blood ·Sabrina Martyr, (unknown), Aldemar Montero, Cynthia E. Dunbar, Elizabeth M. Kang, Phillip Scheinberg, Barbara Weinstein, Xin Tian, Neal S. Young, Adrian Wiestner	2
9	In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity 2013 ·Blood ·Georg Aue, Mohammed Farooqui, Jade Jones, Janet Valdez, Sabrina Martyr, Susan Soto, Maryalice Stetler‐Stevenson, Constance M. Yuan, Adrian Wiestner	6
10	Hematologic, biochemical, and cardiopulmonary effects of l‐arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy 2009 ·European Journal Of Haematology ·Jane A. Little, Kristine Hauser, Sabrina Martyr, (unknown), Irina Marić, Claudia R. Morris, Jung H. Suh, James G. Taylor, Oswaldo Castro, Roberto F. Machado, Gregory J. Kato, Mark T. Gladwin	53
11	Severity of pulmonary hypertension during vaso‐occlusive pain crisis and exercise in patients with sickle cell disease 2006 ·British Journal of Haematology ·Roberto F. Machado, A. Kyle Mack, Sabrina Martyr, Christopher F. Barnett, Peter H. MacArthur, Vandana Sachdev, Inez Ernst, Lori A. Hunter, Wynona Coles, James Nichols, Gregory J. Kato, Mark T. Gladwin	83
12	Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. 2006 ·PubMed ·Jane A. Little, (unknown), Gregory J. Kato, (unknown), Jordan J. Feld, Irina Marić, Sabrina Martyr, James G. Taylor, Roberto F. Machado, Theo Heller, Oswaldo Castro, Mark T. Gladwin	48
13	Levels of soluble endothelium‐derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality 2005 ·British Journal of Haematology ·Gregory J. Kato, Sabrina Martyr, William C. Blackwelder, James S. Nichols, Wynona Coles, Lori A. Hunter, Marie‐Luise Brennan, Stanley L. Hazen, Mark T. Gladwin	162
14	Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension 2005 ·British Journal of Haematology ·Roberto F. Machado, Sabrina Martyr, Gregory J. Kato, Robyn J. Barst, Anastasia Anthi, M. Robinson, Lori A. Hunter, Wynona Coles, (unknown), Christian J. Hunter, Vandana Sachdev, Oswaldo Castro, Mark T. Gladwin	161
15	Pulmonary vascular effects of red blood cells containing S-nitrosated hemoglobin 2004 ·American Journal of Physiology-Heart and Circulatory Physiology ·Steven Deem, Seong Su Kim, (unknown), (unknown), (unknown), Sabrina Martyr, Xunde Wang, Erik R. Swenson, Mark T. Gladwin	21
16	Acute on Chronic Pulmonary Hypertension in Patients with Sickle Cell Disease. 2004 ·Blood ·Gregory J. Kato, Sabrina Martyr, Roberto F. Machado, Vandana Sachdev, Inez Ernst, Lori A. Hunter, Wynona Coles, (unknown), Christian J. Hunter, Mark T. Gladwin	6
17	Pulmonary Hypertension in Sickle Cell Disease: Cardiopulmonary Evaluation and Response to Chronic Phosphodiesterase 5 Inhibitor Therapy. 2004 ·Blood ·Roberto F. Machado, Sabrina Martyr, Anastasia Anthi, Gregory J. Kato, Lori A. Hunter, Wynona Coles, James S. Nichols, Oswaldo Castro, Mark T. Gladwin	11
18	Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation breakdown → 2003 ·Nature Medicine ·(unknown), (unknown), Jack H. Crawford, Rakesh P. Patel, Christopher D. Reiter, Sabrina Martyr, Benjamin Yang, Myron A. Waclawiw, Gloria Zalos, Xiuli Xu, Kris T. Huang, Howard Shields, Daniel B. Kim‐Shapiro, Alan N. Schechter, Richard O. Cannon, Mark T. Gladwin	1412

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact